Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus conversion study after paediatric kidney transplantation
2019-003710-13Phase 3Active
- Sponsor
- Universitätsmedizin Essen
- Start
- Jun 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tacrolimus in kidney transplant (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Tacrolimus 24-hour full AUC bioequivalence. Started Jun 2021; status: active.
02
Drugs
tacrolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2019-003710-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003710-13.